A Phase 1 Open-Label Multicenter Dose-Escalation Dose- Expansion and Dose-Randomization Study of IO-108 as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors.

Brief description of study

You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to assess the Safety, Tolerability, and Efficacy of the study drug (IO-108) individually, and in Combination with the study drug (Pembrolizumab) in subjects with advanced solid tumors. The study also estimates the maximum tolerated dose or maximum administered dose of the study drugs. The study is also being done to learn more about how the study drugs are absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medication during the entire study period.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.